Enzo Biochem, Inc. ($0.01 Par Value) (ENZ): Price and Financial Metrics

Enzo Biochem, Inc. ($0.01 Par Value) (ENZ): $1.38

0.03 (+2.22%)

POWR Rating

Component Grades








ENZ Price/Volume Stats

Current price $1.38 52-week high $2.74
Prev. close $1.35 52-week low $1.00
Day low $1.34 Volume 100,800
Day high $1.38 Avg. volume 96,600
50-day MA $1.35 Dividend yield N/A
200-day MA $1.54 Market Cap 69.68M

ENZ Stock Price Chart Interactive Chart >


  • Value is the dimension where ENZ ranks best; there it ranks ahead of 71.43% of US stocks.
  • The strongest trend for ENZ is in Value, which has been heading up over the past 26 weeks.
  • ENZ's current lowest rank is in the Momentum metric (where it is better than 27.6% of US stocks).

ENZ Stock Summary

  • ENZ's current price/earnings ratio is 2.97, which is higher than only 2.19% of US stocks with positive earnings.
  • With a year-over-year growth in debt of -64.75%, ENZO BIOCHEM INC's debt growth rate surpasses merely 3.13% of about US stocks.
  • As for revenue growth, note that ENZ's revenue has grown -79.16% over the past 12 months; that beats the revenue growth of merely 2.26% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to ENZO BIOCHEM INC, a group of peers worth examining would be SNOA, PMD, STIM, SGHT, and PWFL.
  • ENZ's SEC filings can be seen here. And to visit ENZO BIOCHEM INC's official web site, go to www.enzo.com.

ENZ Valuation Summary

  • In comparison to the median Healthcare stock, ENZ's EV/EBIT ratio is 97.95% lower, now standing at 0.3.
  • Over the past 243 months, ENZ's price/earnings ratio has gone up 3549.6.

Below are key valuation metrics over time for ENZ.

Stock Date P/S P/B P/E EV/EBIT
ENZ 2023-12-29 3.4 0.9 2.9 0.3
ENZ 2023-12-28 3.4 0.9 2.9 0.3
ENZ 2023-12-27 3.4 0.9 2.8 0.3
ENZ 2023-12-26 3.4 0.9 2.9 0.3
ENZ 2023-12-22 3.4 1.0 2.9 0.3
ENZ 2023-12-21 3.4 1.0 2.9 0.3

ENZ Growth Metrics

    Its year over year cash and equivalents growth rate is now at 106.31%.
  • The 4 year price growth rate now stands at -71.51%.
  • The 3 year revenue growth rate now stands at 31.75%.
Over the past 33 months, ENZ's revenue has gone up $18,654,000.

The table below shows ENZ's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 98.828 -19.24 -26.577
2022-06-30 107.071 -16.59 -18.261
2022-03-31 111.6 -7.412 -6.56
2021-12-31 118.175 -4.258 0.3
2021-09-30 115.595 -4.448 5.257
2021-06-30 117.731 0.387 7.875

ENZ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ENZ has a Quality Grade of B, ranking ahead of 78.47% of graded US stocks.
  • ENZ's asset turnover comes in at 1.04 -- ranking 20th of 81 Healthcare stocks.
  • LFMD, RHE, and AHCO are the stocks whose asset turnover ratios are most correlated with ENZ.

The table below shows ENZ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-31 1.040 0.455 0.105
2021-04-30 0.996 0.459 0.019
2021-01-31 0.850 0.414 -0.189
2020-10-31 0.736 0.355 -0.371
2020-07-31 0.646 0.313 -0.499
2020-04-30 0.666 0.288 -0.621

Enzo Biochem, Inc. ($0.01 Par Value) (ENZ) Company Bio

Enzo Biochem, Inc. engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company was founded in 1976 and is based in New York, New York.

ENZ Latest News Stream

Event/Time News Detail
Loading, please wait...

ENZ Latest Social Stream

Loading social stream, please wait...

View Full ENZ Social Stream

Latest ENZ News From Around the Web

Below are the latest news stories about ENZO BIOCHEM INC that investors may wish to consider to help them evaluate ENZ as an investment opportunity.


FARMINGDALE, NY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal year ended July 31, 2023, and also provided a general business update. Fourth Quarter Highlights In July 2023, Enzo Biochem closed on the sale of assets used in the operation of Enzo Clinical Labs for a cash purchase price of $113,250,000, resulting in the full divestment of Enzo’s clinical laborat

Yahoo | November 6, 2023

Steven J. Pully Appointed to Enzo Biochem’s Board of Directors

FARMINGDALE, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading life sciences company, announced today that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023. Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well. “In 2023, Enzo completed the divestiture of Enzo Clinical Labs, Inc. and focused its strategy on growing the life sciences division,” sai

Yahoo | October 30, 2023

Enzo Biochem (NYSE:ENZ) shareholders have endured a 63% loss from investing in the stock five years ago

Generally speaking long term investing is the way to go. But unfortunately, some companies simply don't succeed. For...

Yahoo | October 6, 2023

Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO

FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo’s Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. “We thank Hamid for the commitment he has brought to Enzo Biochem, Inc.” Chairperson of the Board Mary Tagliaferri, MD stated, “Hamid successfully led the Co

Yahoo | September 6, 2023

Here’s Why Laughing Water Capital Made a Position in Enzo Biochem (ENZ)

Laughing Water Capital, an investment management company, released its second-quarter 2023 investor letter. A copy of the same can be downloaded here. In the second quarter, investment in the fund returned 13.8%, net of all fees and expenses, compared to the SP500TR and the R2000 returns of 8.7% and 5.2%, respectively. The fund’s return so far […]

Yahoo | July 31, 2023

Read More 'ENZ' Stories Here

ENZ Price Returns

1-mo 6.15%
3-mo 9.52%
6-mo -9.80%
1-year 17.95%
3-year -52.74%
5-year -60.68%
YTD -0.72%
2023 -2.80%
2022 -55.45%
2021 27.38%
2020 -4.18%
2019 -5.40%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!